Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:687 |
Name | hepatoblastoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer hepatoblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00980460 | Phase III | Irinotecan + Temsirolimus + Vincristine Sulfate Cisplatin + Fluorouracil + Vincristine Sulfate Doxorubicin | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | Active, not recruiting | USA | CAN | BRA | AUS | 2 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | SVK | HUN | FRA | ESP | CZE | CAN | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT03017326 | Phase III | Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Paediatric Hepatic International Tumour Trial (PHITT) | Active, not recruiting | POL | NOR | NLD | ISR | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Active, not recruiting | USA | CAN | AUS | 1 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03533582 | Phase II | Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT04634357 | Phase Ib/II | ET140203 | ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) | Recruiting | USA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04928677 | Phase I | Codrituzumab | A Study of Codrituzumab in Children and Young Adults with Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Recruiting | USA | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |
NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Not yet recruiting | USA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Recruiting | USA | ITA | ESP | DNK | CZE | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |